Company Overview of AnaptysBio, Inc.
AnaptysBio, Inc. focuses on the generation of antibody therapeutics, as well as on the use of somatic hypermutation (SHM) for antibody discovery and optimization. The company’s SHM-XEL platform couples human antibody libraries with in vitro somatic hypermutation in mammalian cells to generate high affinity antibodies that replicates key features of the human immune system. It develops ANB020Its, an anti-IL-33 lead candidate antibody that inhibits IL-33 cytokine function by blocking interaction with receptor at low picomolar potency; a portfolio of antibodies for immuno-oncology to modulate the function of T cell negative regulators, including PD-1, TIM-3, and LAG-3; ANB012, an anti-ActRIIb a...
10421 Pacific Center Court
San Diego, CA 92121
Founded in 2005
Key Executives for AnaptysBio, Inc.
Chief Executive Officer, President and Director
Chief Development Officer
Compensation as of Fiscal Year 2014.
AnaptysBio, Inc. Key Developments
AnaptysBio, Inc. Presents at Credit Suisse 2015 Antibody Day, May-06-2015 12:40 PM
Apr 29 15
AnaptysBio, Inc. Presents at Credit Suisse 2015 Antibody Day, May-06-2015 12:40 PM. Venue: Credit Suisse, One Madison Avenue at 24th Street, 12th Floor, New York, New York, United States. Speakers: Hamza Suria, Chief Executive Officer, President and Director, Marco Londei, Chief Development Officer.
AnaptysBio, Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-15-2015 11:40 AM
Apr 6 15
AnaptysBio, Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-15-2015 11:40 AM. Venue: Westin Grand Central Hotel, New York, New York, United States.
AnaptysBio, Inc. Appoints Gerrit Los as Vice President of Pharmacology
Apr 6 15
AnaptysBio, Inc. announced the appointment of Gerrit Los, Ph.D. as vice president of Pharmacology. Dr. Los will lead translational biology across AnaptysBio's proprietary antibody pipeline, including programs focused upon novel immuno-oncology opportunities. Dr. Los will report to Dr. Macro Londei, AnaptysBio's chief development officer. Dr. Los joins company from Five Prime Therapeutics, where he led translational medicine across several immuno-oncology related biologics.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|